Do US FDA Complete Response Letters Suggest Turn To Less Flexibility In Rare Disease?

 
• By Bridget Silverman
  
US FDA complete response letters have knocked down rare disease applications relying on confirmatory evidence from sponsors from Biohaven to PTC and Immedica (Shutterstock)

More from Complete Response Letters

More from US FDA Performance Tracker